source
- OrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaThe sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.BioSpace · 4d ago↗ source
- Estuary debuts with $103M to develop kidney disease gene therapiesEstuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. Th…Endpoints · 4d ago↗ source
- FDA issues early alert for Edwards Lifesciences’ mitral valve delivery system after reported death, injuryThe FDA has issued an early alert for certain delivery systems used with Edwards Lifesciences’ SAPIEN M3 transcatheter mitral valve replacement system amid serious safety concerns.